CGI Pharmaceuticals, Inc.

Cellular Genomics Raises $22.3 Million in First Close of Series C Financing

Cellular Genomics Raises $22.3 Million in First Close of Series C Financing

January 21, 2004

BRANFORD, Conn., Jan. 21 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a chemical genetics based drug discovery and development company, today announced that it has raised $22.3 million in the initial close of a Series C private equity financing. This Series C Round is being led by Lilly BioVentures, and has been joined by new investors Coastview Capital and Emerging Technology Partners, as well as existing investors including Connecticut Innovations, Flagship Ventures, MPM Capital, and Vector Fund Management.

BG Medicine, Inc.

Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

Beyond Genomics and GlaxoSmithKline Announce Partnership to Apply Systems Biology to Metabolic Diseases

January 28, 2004

Waltham, Mass. and London, U.K. - January 28, 2004 - Beyond Genomics, Inc. (BG) and GlaxoSmithKline (GSK) announced today that they have entered into a research collaboration, option and license agreement in the area of systems biology for the purpose of drug discovery and development in metabolic diseases. This follows a successful pilot relationship between the companies that began in December 2002 and involved the use of BG's proprietary Systems Biology platform to elucidate disease pathways and identify biomarkers of disease state and drug response.

CGI Pharmaceuticals, Inc.

Career straddles clinical, research roles

Career straddles clinical, research roles

February 2, 2004

By Dyke Hendrickson, Mass High Tech, February 2, 2004

If a biotech executive were preparing to approach the Food and Drug Administration with a new drug application, it would be useful for him to be knowledgeable about federal regulation as well as medical science.

Enter Dr. Louis Matis. He is a medical doctor, and also a former physician/researcher with both the FDA and the National Institutes of Health.

TransMedics, Inc.

TransMedics transforms transplant transport

TransMedics transforms transplant transport

February 2, 2004

By Dyke Hendrickson, Mass High Tech, February 2, 2004

Since the inception of organ transplants, many life sciences professionals have found it odd that donated hearts were transported from one medical center to another in Igloo ice coolers that might have been purchased at Building 19. Such a transportation system could soon be history.

TransMedics Inc., a medical device maker in Woburn, recently closed a $27.6 million series B funding round, which will enable it to develop a better way to store and transport human organs.

TransMedics, Inc.

TransMedics, Inc. Raises $27.6 Million in Series B Funding

TransMedics, Inc. Raises $27.6 Million in Series B Funding

January 27, 2004

The TransMedics Portable Organ Preservation System - POPS - Keeps Organs Alive on the Way to Transplant Recipients

Helicos BioSciences Corporation

Helicos Raises $27M In Venture Round

Helicos Raises $27M In Venture Round

February 2, 2004

Firm is latest entrant in tests for genetic data

Stanley N. Lapidus is at it again.

The founder of two Boston-area medical testing companies says he recently completed a $27 million financing round for a new firm he's helped form, called Helicos BioSciences Corp. It will be the latest to enter a field of companies trying to develop tests for genetic data and new ways to study DNA.

Helicos BioSciences Corporation

Helicos BioSciences Launched by Flagship Ventures

Helicos BioSciences Launched by Flagship Ventures

February 2, 2004

Flagship Ventures and Stan Lapidus, whose reputation as a repeat entrepreneur is well known in the biotech industry, have just launched Helicos BioSciences Corporation in Cambridge, MA. Other cofounders and advisors include several of the world's leading academics in the fields of DNA sequencing, cancer research and bioinformatics from Caltech, MIT, Stanford, Harvard and ISB. Stan spent the last 18 months with Flagship as a Venture Partner, helping a number of its portfolio companies grow while searching for a new venture creation challenge.

Acceleron Pharma, Inc.

Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding

Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding

February 13, 2004

BOSTON, MA - February 13, 2004 - Acceleron Pharma, a biopharmaceutical company developing drugs to treat musculoskeletal and metabolic disorders, announced today that it has raised $25 million in its first round of private equity financing. The company has an exceptional team and a set of proprietary approaches that will enable it to develop a deep pipeline of products by targeting a large and high potential family of growth and differentiation factors.

Morphotek, Inc.

Morphotek Inc. Closes $26 Million Series C Financing

Morphotek Inc. Closes $26 Million Series C Financing

February 18, 2004

EXTON, PA - February 18, 2004 - Morphotek Inc. announced today the closing of its $26 million Series C financing, a private placement of preferred stock with existing and new investors, led by Forward Ventures of San Diego, California.

Selventa

Genstruct Appoints Douglas A. Lauffenburger, Ph.D., To Board of Directors

Genstruct Appoints Douglas A. Lauffenburger, Ph.D., To Board of Directors

February 24, 2004

Tuesday, February 24, 2004, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biopharmaceutical company that is leading the effort to solve complex biological problems using knowledge modeling and logical simulation, today announced the appointment of Douglas A. Lauffenburger, Ph.D., to its Board of Directors.